Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Post by smush74on Aug 11, 2013 12:25pm
245 Views
Post# 21662233

comments appreciated

comments appreciated
Doing more research on the drug, opinions and views are welcome and appreciated. First off I diddn't realize that it was a 15  to 20 week medication to illiminate the disease. So I am going to assume that the incidence of this disease will continue in the population and probably increase as a perentage. So sales should continue. My second point would be on finding testimonials on its effectiveness. Haven't found much but I will also assume that since it is new and acne is not something teens like talking about so not surprising. The one thing that did stand out were all the possible side effects and having to be part of the ishare program. What I found was that many pharmacies were not part of this group. I do applaud Ranbaxy with their coupon for the drug to allow as much of the population to get access. Not very different from Fampyra which gave patients one month free trials for those with MS (I'm a recipient) to see if it works as effectiveness would be shown within two weeks.

The one thing that did stand  out were the side effects, not only for absorica but most accutane based products. Here is where I would appreciate any views. Would you think that at some point it may impact sales and even market share. Everybody says the market is "x" for the US but i'm guessing not everybody who suffers from this will want to have accutane or absorica for that reason.

Thanks
Bullboard Posts